Table 3.
Summary of Results for Selected Studies Utilizing EUS-Guided RFA for PCN Therapy.
| Author | Study Year | Number of Treated Patients | Number of Treated Lesions | Efficacy on Follow-Up Imaging **, n (%) | Adverse Events, (n) | ||||
|---|---|---|---|---|---|---|---|---|---|
| MCN | IPMN | Other * | Incomplete Response | Partial Response | Complete Response | ||||
| Pai et al. [11] | 2015 | 6 | 4 | 1 | 1 | 0 (0) | 4 (67) | 2 (33) | Mild abdominal pain (2) |
| Barthet et al. [66] | 2019 | 17 | 1 | 16 | 0 | 5 (29) | 1 (6) | 11 (65) | Jejunal perforation (1) |
| Oh et al. [68] | 2021 | 13 | 0 | 0 | 13 | 5 (38) | 8 (62) | 0 (0) | Mild abdominal pain (1) |
| Younis et al. [67] | 2022 | 5 | 1 | 4 | 0 | 1 (20) | 1 (20) | 3 (60) | Mild abdominal pain (2); Acute pancreatitis (1) |
* The designation of “Other” includes patients treated in the above studies for cystic lesions that are non-neoplastic (i.e., pseudocysts), neoplastic without malignant potential (i.e., SCNs), or indeterminate based on pre-procedural analysis. Although the scope of this review focuses on the use of EUS-guided ablative procedures in the treatment of neoplastic cysts capable of malignant transformation (i.e., MCNs and IPMNs), this column is included in the table for the purpose of completeness. ** Complete response is defined as the radiographic absence of residual lesion on post-procedural imaging. Incomplete response is defined as either persistent or enlarged residual lesion on post-procedural imaging. If the study authors noted reduction in lesion size without resolution on post-procedural imaging, this is considered a partial response; if this was not recorded by the study authors, these lesions are categorized as incomplete response.